Trevor McCaw became chief commercial officer of TriSalus Life Sciences, an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors.
Recce Pharmaceuticals Ltd. tapped Michele Dilizia as chief scientific officer. Dilizia also continues her role as executive director and as a member of the board of directors.
X4 Pharmaceuticals Inc. appointed Art Taveras, Ph.D., as chief scientific officer.
Sio Gene Therapies promoted Parag. V. Meswani, Pharm.D., from senior VP, Commercial Strategy & Operations, to chief commercial officer.
Pharming Group N.V. appointed Jeroen Wakkerman as chief financial officer.
OncoQuest Pharmaceuticals appointed Dr. Sunil Gupta as chief medical officer.
CalciMedica Inc. named Daniel Geffken as interim chief financial officer.
A new breed of key opinion leader (KOL) has arisen, one that is not necessarily found within that original conference and journal and clinical trial paradigm – and the impact of the COVID pandemic has just magnified this new breed’s significance and influence.
Nearly nine in 10 (88 percent) of healthcare providers who currently use telehealth have seen an increase in the use of telehealth as a result of the coronavirus pandemic – with 71 percent reporting a great increase, according to a survey by the healthcare communication platform provider TigerConnect.
The health services provider Harvard Pilgrim Health Care announced the launch of SimplyVirtual, an innovative model for health care that gives members access to virtual visits with primary care providers and care team support through its existing partner, Doctor On Demand.
